Trial · NCT02469597
Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis
NCT02469597, Phase 2, Completed, Northwell Health; results first posted 2016-08-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis. Trials, record NCT02469597. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02469597
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis
- NCT number
- NCT02469597
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 46 participants, actual
- Lead sponsor
- Northwell Health
- Conditions
- Bronchiolitis
- Interventions
- Furosemide, Placebo
- First posted
- 2015-06-11
- Last updated
- 2016-08-12
- Results first posted
- 2016-08-12
- Limitations and caveats
- The trial was ended early due to recruitment difficulties.
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Respiratory Rate | 2 hours after medication adminstration | |
| Primary | Respiratory Rate | 4 hours after medication adminstration | |
| Primary | Oxygen Saturation | 2 hours after medication adminstration | |
| Primary | Oxygen Saturation | 4 hours after medication adminstration | |
| Secondary | Patient Needing Endotracheal Intubation | Within 72 hours of medication administration | |
| Secondary | Length of Hospital Stay | Participants will be followed for the duration of hospital stay up to 1 week |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Respiratory Rate | 2 hours after medication adminstration | Percentage change in respiratory rate | LEAST_SQUARES_MEAN | |
| PRIMARY | Respiratory Rate | 4 hours after medication adminstration | Percentage change in respiratory rate | LEAST_SQUARES_MEAN | |
| PRIMARY | Oxygen Saturation | 2 hours after medication adminstration | Percentage change in oxygen saturation | LEAST_SQUARES_MEAN | |
| PRIMARY | Oxygen Saturation | 4 hours after medication adminstration | Percentage change in oxygen saturation | LEAST_SQUARES_MEAN | |
| SECONDARY | Patient Needing Endotracheal Intubation | Within 72 hours of medication administration | participants | NUMBER | |
| SECONDARY | Length of Hospital Stay | Participants will be followed for the duration of hospital stay up to 1 week | Days | LEAST_SQUARES_MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Respiratory Rate | Single Dose of Furosemide | -3.7 | Standard Error 5.5 | Percentage change in respiratory rate | |
| Respiratory Rate | Placebo | -1.7 | Standard Error 5.3 | Percentage change in respiratory rate | |
| Respiratory Rate | Single Dose of Furosemide | -2.8 | Standard Error 6.5 | Percentage change in respiratory rate | |
| Respiratory Rate | Placebo | -5.4 | Standard Error 6.3 | Percentage change in respiratory rate | |
| Oxygen Saturation | Single Dose of Furosemide | -0.14 | Standard Error 0.67 | Percentage change in oxygen saturation | |
| Oxygen Saturation | Placebo | 0.2 | Standard Error 0.6 | Percentage change in oxygen saturation | |
| Oxygen Saturation | Single Dose of Furosemide | -0.19 | Standard Error 0.58 | Percentage change in oxygen saturation | |
| Oxygen Saturation | Placebo | 0.29 | Standard Error 0.84 | Percentage change in oxygen saturation | |
| Patient Needing Endotracheal Intubation | Single Dose of Furosemide | 0 | participants | ||
| Patient Needing Endotracheal Intubation | Placebo | 0 | participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Single Dose of Furosemide | 22 | |
| Overall Study | STARTED | Placebo | 24 | |
| Overall Study | COMPLETED | Single Dose of Furosemide | 22 | |
| Overall Study | COMPLETED | Placebo | 24 | |
| Overall Study | NOT COMPLETED | Single Dose of Furosemide | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Single Dose of Furosemide | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Single Dose of Furosemide | 0 | 22 |
| Total, other adverse events | Placebo | 0 | 24 |
| Total, serious adverse events | Single Dose of Furosemide | 0 | 22 |
| Total, serious adverse events | Placebo | 0 | 24 |
Source ClinicalTrials.gov
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Single Dose of Furosemide vs Placebo: Patient Needing Endotracheal Intubation | Trial comparisons |
| Single Dose of Furosemide vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02469597
GET https://conductscience.org/api/trials/v1/NCT02469597/registered